Overview

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Continent Pharmaceutical Co, Ltd.
Collaborators:
GNI-EPS Pharmaceuticals, Inc. (GNI Group)
Shanghai Genomics, Inc.
Treatments:
Pirfenidone